Clinical Trials
10 trialsNCT06789172 2026-05-22
INVOKE
Epkin
Phase 1 Recruiting
NCT04715191 2026-04-06
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Baylor College of Medicine
Phase 1 Recruiting
NCT05103631 2026-03-06
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors
Baylor College of Medicine
Phase 1 Active not recruiting
NCT07148050 2026-02-17
IMPACT
Seattle Children's Hospital
Phase 1 Recruiting
NCT04377932 2026-01-21
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Baylor College of Medicine
Phase 1 Active not recruiting
NCT07224568 2025-11-04
INTERCEPT
Seattle Children's Hospital
Phase 1 Not yet recruiting
NCT06198296 2025-11-03
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
Baylor College of Medicine
Phase 1 Recruiting
NCT00413075 2015-07-08
Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma
Valerio Therapeutics
Phase 1 Completed
NCT00413322 2015-07-08
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
Valerio Therapeutics
Phase 1 Completed
NCT00069940 2010-12-28
Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor
Dana-Farber Cancer Institute
Phase 1 Completed